Every 8-K that eXoZymes Inc (EXOZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EXOZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXOZ filings page.
eXoZymes Inc. completed a $639,990 underwritten unit offering, selling 35,555 units at $18.00 each. Each unit consists of one share of common stock, priced at $8.99, and one warrant to buy one share.
The company plans to use net proceeds for its N‑trans‑caffeoyltyramine (NCT) technology, additional products, research and development, and general corporate purposes. Investor warrants become exercisable on June 5, 2027 at $11.24 per share, can be redeemed by the company once trading and registration conditions are met, and include a potential Warrant Reset that can lower the exercise price to $0.001 if specific holding and pricing conditions are satisfied.
eXoZymes Inc. announced it has received a Notice of Award from the National Institute of General Medical Sciences of the NIH for a Phase IIB SBIR grant totaling $2,028,518. The two-year, non-dilutive grant is expected to begin on July 1, 2026 and supports development of rare cannabinoids and engineered cannabinoid analogs for pharmaceutical evaluation.
This award adds a second biosolution to eXoZymes’ pipeline after its NCT program and brings the company’s total non-dilutive funding to $19.7 million. Management highlights the grant as validation of its AI-enhanced, cell-free enzyme platform for scalable production of high-purity cannabinoids and new-to-nature molecules targeting future licensing and partnership opportunities.
eXoZymes Inc. completed an underwritten public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds, including a partial exercise of the underwriters’ over-allotment option.
The company sold units combining common shares and warrants, with MDB Capital as sole book‑running manager, and plans to use the net proceeds to advance its N‑trans‑caffeoyltyramine (NCT) program, additional product opportunities, research and development, and general corporate and working capital needs.
eXoZymes Inc. is raising approximately $5.33 million through an underwritten public unit offering of common stock and warrants priced at $18.00 per unit. Each unit includes two shares and one warrant, with the offering made off an effective Form S-3 shelf registration.
The underwriter has a 45-day option to buy additional units, which could lift gross proceeds to $6.13 million before fees. Warrants become exercisable one year after the offering at $11.24 per share, can be redeemed once the stock trades at or above $17.98 for twenty out of thirty trading days, and include a reset feature that can cut the exercise price to $0.001 if eXoZymes sells stock or convertible securities below $8.99 within twelve months, subject to strict holding-period conditions for original investors.
Net proceeds, after underwriting commissions of about $0.37 million and estimated offering expenses of $0.25 million, are earmarked to advance the company’s N-trans-caffeoyltyramine (NCT) programs, other research and development, and general corporate and working capital needs.
eXoZymes Inc. filed a current report to share an updated investor presentation dated May 7, 2026. The presentation is being provided to potential underwriters, other offering participants, and investors in connection with a proposed public offering of the company’s securities.
The report lists the presentation as Exhibit 99.1 and includes a cover page interactive data file as Exhibit 104. eXoZymes is a Nevada corporation whose common stock trades on the Nasdaq Capital Market under the symbol EXOZ.
eXoZymes Inc.
eXoZymes Inc. filed a current report to make public an updated Investor Presentation for its NCTx business as of March 30, 2026. The company characterizes this under an Other Events item, using the 8-K to furnish the new presentation as Exhibit 99.1.
Exozymes Inc. filed a Form 8-K to inform investors that it issued a press release dated January 29, 2026. The release announces the advancing commercial readiness of the company’s initial NCT pilot run, indicating progress toward moving this early-stage initiative closer to potential commercial use.
ExoZymes Inc. filed a current report to announce that it has issued a press release about scaling up production of NCT using its exozymes technology. The company classifies this as an "Other Event," highlighting operational progress rather than a financial update or major transaction. The press release, dated December 11, 2025, is furnished as an exhibit to the report, indicating the company wants investors informed about this step in its production capabilities while remaining listed on the Nasdaq Capital Market under the symbol EXOZ.
eXoZymes Inc. filed an 8-K announcing an updated Investor Presentation as of November 13, 2025. The update, tied to its NCTx business, is furnished under Item 8.01 (Other Events) and provided as Exhibit 99.1.
The company’s common stock trades on the Nasdaq Capital Market under the symbol EXOZ. The report lists the company’s principal office at 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016.
eXoZymes Inc. filed a current report to make public an updated Investor Presentation as of September 30, 2025. The company, which is listed on the Nasdaq Capital Market under the symbol EXOZ, is using this report to formally furnish the latest version of its presentation to investors and analysts.
The presentation is included as Exhibit 99.1 and is described as an Investor Presentation of eXoZymes Inc. as of September 30, 2025. No new financial results, transactions, or other specific operating updates are detailed in the text of this report itself.